GT Biopharma, Inc. (GTBP) › Cash & EquivalentsGT Biopharma, Inc. (GTBP) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2009-12-31: $1.29M2010-12-31: $54.0K2011-12-31: $92.0K2012-09-30: $61.0K2012-12-31: $123.0K2013-12-31: $43.0K2014-12-31: $855.0K2015-12-31: $47.0K2016-12-31: $19.0K2017-12-31: $576.0K2018-12-31: $60.0K2019-12-31: $28.0K2020-12-31: $5.30M2021-12-31: $8.97M2022-12-31: $5.67M2023-12-31: $1.08M2024-12-31: $3.95M2025-12-31: $6.81M$6.81M2009-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$6.81M+72.4%2026-03-02Balance as of period end2024-12-31$3.95M+266.2%2026-03-02Balance as of period end2023-12-31$1.08M-81.0%2025-02-21Balance as of period end2022-12-31$5.67M-36.8%2024-03-26Balance as of period end2021-12-31$8.97M+69.3%2023-03-30Balance as of period end2020-12-31$5.30M+18817.9%2021-04-16Balance as of period end2019-12-31$28.0K-53.3%2021-04-16Balance as of period end2018-12-31$60.0K-89.6%2021-04-16Balance as of period end2017-12-31$576.0K+2931.6%2020-03-27Balance as of period end2016-12-31$19.0K-59.6%2019-03-29Balance as of period end2015-12-31$47.0K-94.5%2018-03-01Balance as of period end2014-12-31$855.0K+1888.4%2018-02-28Balance as of period end2013-12-31$43.0K-65.0%2018-02-28Balance as of period end2012-12-31$123.0K—2015-03-31Balance as of period end2012-09-30$61.0K—2015-01-08Balance as of period end2011-12-31$92.0K+70.4%2015-01-08Balance as of period end2010-12-31$54.0K-95.8%2014-11-18Balance as of period end2009-12-31$1.29M—2012-04-16Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)